Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
1 The global anti-obesity drug market is expected to reach $82.55 billion (USD) by 2032, driven by a compound annual growth rate (CAGR) of 18.01% from 2025 to 2032
The demand for GLP-1 medications, which are used to treat type 2 diabetes and obesity, has surged in recent years
Reduction of Major Cardiovascular Events The SELECT trial of semaglutide (vs placebo) will be presented in November at the American Heart Association
Less than 0.02 percent
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
A meta-analysis published in "Mayo Clinic Proceedings" reviewed multiple studies and concluded that L-Carnitine supplementation can improve heart function and reduce the risk of cardiac events in patients with coronary artery disease
US$ 23.92
US$ 22.55
US$ 27.52
